Literature DB >> 25104816

Nomogram for predicting symptom severity during radiation therapy for head and neck cancer.

Tommy Sheu1, Clifton David Fuller2, Tito R Mendoza3, Adam S Garden2, William H Morrison2, Beth M Beadle2, Jack Phan2, Steven J Frank2, Ehab Y Hanna4, Charles Lu5, Charles S Cleeland3, David I Rosenthal2, G Brandon Gunn6.   

Abstract

OBJECTIVES: Radiation therapy (RT), with or without chemotherapy, can cause significant acute toxicity among patients treated for head and neck cancer (HNC), but predicting, before treatment, who will experience a particular toxicity or symptom is difficult. We created and evaluated 2 multivariate models and generated a nomogram to predict symptom severity during RT based on a patient-reported outcome (PRO) instrument, the MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN). STUDY
DESIGN: This was a prospective, longitudinal, questionnaire-based study.
SETTING: Tertiary cancer care center. SUBJECTS AND METHODS: Subjects were 264 patients with HNC (mostly oropharyngeal) who had completed the MDASI-HN before and during therapy. Pretreatment variables were correlated with MDASI-HN symptom scores during therapy with multivariate modeling and then were correlated with the composite MDASI-HN score during week 5 of therapy.
RESULTS: A multivariate model incorporating pretreatment PROs better predicted MDASI-HN symptom scores during treatment than did a model based on clinical variables and physician-rated patient performance status alone (Akaike information criterion = 1442.5 vs 1459.9). In the most parsimonious model, pretreatment MDASI-HN symptom severity (P < .001), concurrent chemotherapy (P = .006), primary tumor site (P = .016), and receipt of definitive (rather than adjuvant) RT (P = .044) correlated with MDASI-HN symptom scores during week 5. That model was used to construct a nomogram.
CONCLUSION: Our model demonstrates the value of incorporating baseline PROs, in addition to disease and treatment characteristics, to predict patient symptom burden during therapy. Although additional investigation and validation are required, PRO-inclusive prediction tools can be useful for improving symptom interventions and expectations for patients being treated for HNC. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2014.

Entities:  

Keywords:  MD Anderson Symptom Inventory–Head and Neck Module; nomogram; patient-reported outcome; prediction tool; symptom burden

Mesh:

Year:  2014        PMID: 25104816      PMCID: PMC4184965          DOI: 10.1177/0194599814545746

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  26 in total

Review 1.  Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.

Authors:  Charles S Cleeland; Jeff A Sloan
Journal:  J Pain Symptom Manage       Date:  2010-06       Impact factor: 3.612

Review 2.  Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

Authors:  Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers
Journal:  Eur Urol       Date:  2010-08-06       Impact factor: 20.096

3.  Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.

Authors:  Quynh-Thu Le; Harold E Kim; Charles J Schneider; Györgyi Muraközy; Krzysztof Skladowski; Sabine Reinisch; Yuhchyau Chen; Michael Hickey; May Mo; Mon-Gy Chen; Dietmar Berger; Richard Lizambri; Michael Henke
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

4.  Orofacial pain and predictors in oral squamous cell carcinoma patients receiving treatment.

Authors:  Shu-Ching Chen; Chun-Ta Liao; Joseph Tung-Chien Chang
Journal:  Oral Oncol       Date:  2010-12-13       Impact factor: 5.337

5.  Association of age and symptom burden in patients with head and neck cancer.

Authors:  Stewart M Bond; Mary S Dietrich; Barbara A Murphy
Journal:  ORL Head Neck Nurs       Date:  2011

6.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

7.  Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy.

Authors:  Barbara A Murphy; Jennifer L Beaumont; John Isitt; Adam S Garden; Clement K Gwede; Andy M Trotti; Ruby F Meredith; Joel B Epstein; Quynh-Thu Le; David M Brizel; Lisa A Bellm; Nancy Wells; David Cella
Journal:  J Pain Symptom Manage       Date:  2009-07-15       Impact factor: 3.612

Review 8.  Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials.

Authors:  Dennis C Turk; Robert H Dworkin; Michael P McDermott; Nicholas Bellamy; Laurie B Burke; Julie M Chandler; Charles S Cleeland; Penney Cowan; Rozalina Dimitrova; John T Farrar; Sharon Hertz; Joseph F Heyse; Smriti Iyengar; Alejandro R Jadad; Gary W Jay; John A Jermano; Nathaniel P Katz; Donald C Manning; Susan Martin; Mitchell B Max; Patrick McGrath; Henry J McQuay; Steve Quessy; Bob A Rappaport; Dennis A Revicki; Margaret Rothman; Joseph W Stauffer; Ola Svensson; Richard E White; James Witter
Journal:  Pain       Date:  2008-08-15       Impact factor: 6.961

9.  Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.

Authors:  Joseph K Salama; Kerstin M Stenson; Marcy A List; Loren K Mell; Ellen Maccracken; Ezra E Cohen; Elizabeth Blair; Everett E Vokes; Daniel J Haraf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-10

Review 10.  The prognostic significance of patient-reported outcomes in cancer clinical trials.

Authors:  Carolyn C Gotay; Crissy T Kawamoto; Andrew Bottomley; Fabio Efficace
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

View more
  10 in total

1.  Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors.

Authors:  Puja Aggarwal; Jhankruti S Zaveri; Ryan P Goepfert; Qiuling Shi; Xianglin L Du; Michael Swartz; G Brandon Gunn; Stephen Y Lai; C David Fuller; Ehab Y Hanna; David I Rosenthal; Jan S Lewin; Linda B Piller; Katherine A Hutcheson
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

2.  Computerized patient-reported symptom assessment in radiotherapy: a pilot randomized, controlled trial.

Authors:  Erik K Fromme; Emma B Holliday; Lillian M Nail; Karen S Lyons; Michelle R Hribar; Charles R Thomas
Journal:  Support Care Cancer       Date:  2015-10-16       Impact factor: 3.603

3.  Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies.

Authors:  Arash O Naghavi; Michelle I Echevarria; G Daniel Grass; Tobin J Strom; Yazan A Abuodeh; Kamran A Ahmed; Youngchul Kim; Andy M Trotti; Louis B Harrison; Kosj Yamoah; Jimmy J Caudell
Journal:  Cancer       Date:  2016-08-01       Impact factor: 6.860

4.  Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.

Authors:  Matthew J Ferris; Jim Zhong; Jeffrey M Switchenko; Kristin A Higgins; Richard J Cassidy; Mark W McDonald; Bree R Eaton; Kirtesh R Patel; Conor E Steuer; H Michael Baddour; Andrew H Miller; Deborah W Bruner; Canhua Xiao; Jonathan J Beitler
Journal:  Radiother Oncol       Date:  2017-08-18       Impact factor: 6.280

5.  Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module.

Authors:  G Brandon Gunn; Banu Atalar; Tito R Mendoza; Charles S Cleeland; Uğur Selek; Enis Özyar; David I Rosenthal
Journal:  Balkan Med J       Date:  2016-05-01       Impact factor: 2.021

6.  Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients.

Authors:  Na Li; Jiajia Lu; Duanxiang Xia; Xuetong Jiang; Xiaomeng Wen; Xia Qin; Ying Chen; Teng Wang
Journal:  J Gastrointest Oncol       Date:  2022-02

7.  Predicting toxicity for head and neck cancer patients undergoing radiation therapy: an independent and external validation of MDASI-HN based nomogram.

Authors:  Nishant Vidyasagar; Janaki Manur Gururajachar
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-19

8.  Construction and validation of a nomogram to predict overall survival in patients with inflammatory breast cancer.

Authors:  Jian-Dong Diao; Li-Xia Ma; Mei-Yang Sun; Chun-Jiao Wu; Li-Juan Wang; Yan-Ling Liu; Yong-Jing Yang
Journal:  Cancer Med       Date:  2019-08-12       Impact factor: 4.452

9.  A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery.

Authors:  Xin Chai; Mei-Yang Sun; Hong-Yao Jia; Min Wang; Ling Cao; Zhi-Wen Li; Dun-Wei Wang
Journal:  PeerJ       Date:  2019-10-14       Impact factor: 2.984

10.  External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort.

Authors:  Tim Rattay; Petra Seibold; Miguel E Aguado-Barrera; Manuel Altabas; David Azria; Gillian C Barnett; Renée Bultijnck; Jenny Chang-Claude; Ananya Choudhury; Charlotte E Coles; Alison M Dunning; Rebecca M Elliott; Marie-Pierre Farcy Jacquet; Sara Gutiérrez-Enríquez; Kerstie Johnson; Anusha Müller; Giselle Post; Tiziana Rancati; Victoria Reyes; Barry S Rosenstein; Dirk De Ruysscher; Maria C de Santis; Elena Sperk; Hilary Stobart; R Paul Symonds; Begoña Taboada-Valladares; Ana Vega; Liv Veldeman; Adam J Webb; Catharine M West; Riccardo Valdagni; Christopher J Talbot
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.